Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its earnings results on Monday. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02, Briefing.com reports. The business had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The company’s revenue was up 41.5% on a year-over-year basis.

Supernus Pharmaceuticals (NASDAQ SUPN) traded down $4.60 during midday trading on Tuesday, reaching $36.50. 241,859 shares of the company’s stock traded hands, compared to its average volume of 435,823. Supernus Pharmaceuticals has a fifty-two week low of $18.25 and a fifty-two week high of $50.04. The company has a quick ratio of 1.74, a current ratio of 1.94 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1,850.00, a PE ratio of 36.89, a PEG ratio of 1.84 and a beta of 1.30.

ILLEGAL ACTIVITY NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/supernus-pharmaceuticals-inc-supn-announces-quarterly-earnings-results-beats-estimates-by-0-02-eps/1685155.html.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 3,709 shares of the firm’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total value of $167,758.07. Following the sale, the vice president now owns 17,500 shares of the company’s stock, valued at approximately $791,525. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The disclosure for this sale can be found here. Insiders sold a total of 153,709 shares of company stock worth $7,223,108 over the last quarter. Corporate insiders own 6.70% of the company’s stock.

Several equities research analysts have recently commented on SUPN shares. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. FBR & Co started coverage on shares of Supernus Pharmaceuticals in a research report on Thursday, October 19th. They issued a “buy” rating and a $53.00 price objective for the company. Piper Jaffray Companies reissued a “hold” rating and set a $45.00 target price on shares of Supernus Pharmaceuticals in a research report on Friday, September 8th. Stifel Nicolaus reissued a “buy” rating and set a $47.00 target price (up from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Finally, Janney Montgomery Scott started coverage on shares of Supernus Pharmaceuticals in a research report on Friday, July 14th. They set a “neutral” rating and a $47.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $49.78.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.